Eli Lilly and Company (LLY) Revenue & Revenue Breakdown
Eli Lilly and Company Revenue Highlights
Latest Revenue (Y)
$34.12B
Latest Revenue (Q)
$11.30B
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Eli Lilly and Company Revenue by Period
Eli Lilly and Company Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $34.12B | 19.56% |
| 2022-12-31 | $28.54B | 0.79% |
| 2021-12-31 | $28.32B | 15.40% |
| 2020-12-31 | $24.54B | 9.95% |
| 2019-12-31 | $22.32B | 3.84% |
| 2018-12-31 | $21.49B | -6.03% |
| 2017-12-31 | $22.87B | 7.77% |
| 2016-12-31 | $21.22B | 6.33% |
| 2015-12-31 | $19.96B | 1.75% |
| 2014-12-31 | $19.62B | -15.13% |
| 2013-12-31 | $23.11B | 2.25% |
| 2012-12-31 | $22.60B | -6.93% |
| 2011-12-31 | $24.29B | 5.25% |
| 2010-12-31 | $23.08B | 5.68% |
| 2009-12-31 | $21.84B | 7.15% |
| 2008-12-31 | $20.38B | 9.36% |
| 2007-12-31 | $18.63B | 18.75% |
| 2006-12-31 | $15.69B | 7.14% |
| 2005-12-31 | $14.65B | 5.68% |
| 2004-12-31 | $13.86B | 10.14% |
| 2003-12-31 | $12.58B | 13.59% |
| 2002-12-31 | $11.08B | -4.03% |
| 2001-12-31 | $11.54B | 6.26% |
| 2000-12-31 | $10.86B | 8.59% |
| 1999-12-31 | $10.00B | 8.29% |
| 1998-12-31 | $9.24B | 8.44% |
| 1997-12-31 | $8.52B | 15.94% |
| 1996-12-31 | $7.35B | 8.62% |
| 1995-12-31 | $6.76B | 18.42% |
| 1994-12-31 | $5.71B | -11.48% |
| 1993-12-31 | $6.45B | - |
Eli Lilly and Company generated $34.12B in revenue during NA 2023, up 19.56% compared to the previous quarter, and up 158.77% compared to the same period a year ago.
Eli Lilly and Company Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $11.30B | 28.91% |
| 2024-03-31 | $8.77B | -6.26% |
| 2023-12-31 | $9.35B | -1.53% |
| 2023-09-30 | $9.50B | 14.27% |
| 2023-06-30 | $8.31B | 19.43% |
| 2023-03-31 | $6.96B | -4.68% |
| 2022-12-31 | $7.30B | 5.19% |
| 2022-09-30 | $6.94B | 6.99% |
| 2022-06-30 | $6.49B | -16.93% |
| 2022-03-31 | $7.81B | -2.37% |
| 2021-12-31 | $8.00B | 18.12% |
| 2021-09-30 | $6.77B | 0.49% |
| 2021-06-30 | $6.74B | -0.96% |
| 2021-03-31 | $6.81B | -8.53% |
| 2020-12-31 | $7.44B | 29.60% |
| 2020-09-30 | $5.74B | 4.39% |
| 2020-06-30 | $5.50B | -6.15% |
| 2020-03-31 | $5.86B | -4.16% |
| 2019-12-31 | $6.11B | 11.64% |
| 2019-09-30 | $5.48B | -2.84% |
| 2019-06-30 | $5.64B | 10.69% |
| 2019-03-31 | $5.09B | -20.91% |
| 2018-12-31 | $6.44B | 6.21% |
| 2018-09-30 | $6.06B | -4.62% |
| 2018-06-30 | $6.36B | 11.49% |
| 2018-03-31 | $5.70B | -7.48% |
| 2017-12-31 | $6.16B | 8.88% |
| 2017-09-30 | $5.66B | -2.86% |
| 2017-06-30 | $5.82B | 11.40% |
| 2017-03-31 | $5.23B | -9.24% |
| 2016-12-31 | $5.76B | 10.96% |
| 2016-09-30 | $5.19B | -3.94% |
| 2016-06-30 | $5.40B | 11.09% |
| 2016-03-31 | $4.87B | -9.50% |
| 2015-12-31 | $5.38B | 8.39% |
| 2015-09-30 | $4.96B | -0.38% |
| 2015-06-30 | $4.98B | 7.19% |
| 2015-03-31 | $4.64B | -9.31% |
| 2014-12-31 | $5.12B | 5.04% |
| 2014-09-30 | $4.88B | -1.22% |
| 2014-06-30 | $4.94B | 5.39% |
| 2014-03-31 | $4.68B | -19.38% |
| 2013-12-31 | $5.81B | 0.63% |
| 2013-09-30 | $5.77B | -2.65% |
| 2013-06-30 | $5.93B | 5.85% |
| 2013-03-31 | $5.60B | -5.97% |
| 2012-12-31 | $5.96B | 9.44% |
| 2012-09-30 | $5.44B | -2.81% |
| 2012-06-30 | $5.60B | -0.02% |
| 2012-03-31 | $5.60B | -7.35% |
| 2011-12-31 | $6.05B | -1.65% |
| 2011-09-30 | $6.15B | -1.68% |
| 2011-06-30 | $6.25B | 7.08% |
| 2011-03-31 | $5.84B | -5.62% |
| 2010-12-31 | $6.19B | 9.41% |
| 2010-09-30 | $5.65B | -1.63% |
| 2010-06-30 | $5.75B | 4.80% |
| 2010-03-31 | $5.49B | -7.56% |
| 2009-12-31 | $5.93B | 6.69% |
| 2009-09-30 | $5.56B | 5.09% |
| 2009-06-30 | $5.29B | 4.87% |
| 2009-03-31 | $5.05B | -3.14% |
| 2008-12-31 | $5.21B | 0.02% |
| 2008-09-30 | $5.21B | 1.15% |
| 2008-06-30 | $5.15B | 7.13% |
| 2008-03-31 | $4.81B | -7.36% |
| 2007-12-31 | $5.19B | - |
Eli Lilly and Company generated $11.30B in revenue during Q2 2024, up 28.91% compared to the previous quarter, and up 162.40% compared to the same period a year ago.
Eli Lilly and Company Revenue Breakdown
Eli Lilly and Company Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Collaboration and Other Revenue | $5.31B | $3.08B | $2.36B | $1.84B | $1.94B |
| Product | $28.81B | $25.46B | $25.96B | $22.69B | $20.38B |
| Trajenta (BI) | - | $383.70M | - | - | - |
| Royalty | - | $163.40M | $175.00M | $135.60M | $301.50M |
| COVID-19 Antibodies | - | - | $2.24B | - | - |
| TYVYT | - | - | - | $308.70M | - |
Eli Lilly and Company's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (84.44%), and Collaboration and Other Revenue (15.56%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Product | $41.30M | $42.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Oncology | $1.81B | $1.75B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Neuroscience | $389.10M | $1.77B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Immunology | $834.00M | $986.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Diabetes | - | $4.72B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Neuroscience | - | $118.20M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Oncology | - | $275.40M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cialis | - | $86.80M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Immunology | - | $11.40M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Diabetes | - | $141.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Olumiant | - | $231.40M | $406.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Mounjaro | - | $1.41B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Jardiance | - | $700.80M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Humulin | - | $206.70M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Humalog | - | $395.40M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Forteo | - | $146.40M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Erbitux | - | $153.90M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Emgality | - | $168.50M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cyramza | - | $224.10M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| COVID-19 Antibodies | - | - | $1.06B | $217.10M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Basaglar | - | $179.60M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Baqsimi | - | $13.10M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Alimta | - | $53.50M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Zyprexa | - | $1.48B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Verzenio | - | $1.04B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Trulicity | - | $1.67B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Taltz | - | $744.20M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Trajenta (BI) | - | - | $103.60M | $85.80M | $90.70M | $103.80M | $92.60M | $96.10M | - | - | - | - | - | - | - | - | - | - | - | - |
| Collaboration and Other Revenue | - | - | $1.33B | $721.80M | $962.00M | $822.40M | $617.10M | $677.10M | $621.50M | $669.60M | $485.60M | $507.50M | $459.50M | $421.70M | $456.30M | $579.70M | $494.60M | $468.00M | $399.90M | - |
| Product | - | - | $6.98B | $6.24B | $6.34B | $6.12B | $5.87B | $7.13B | $7.38B | $6.07B | $6.32B | $6.93B | $5.28B | $5.08B | $5.40B | $5.53B | $4.98B | $5.17B | $4.69B | - |
| Royalty | - | - | $30.30M | $25.10M | $32.50M | $43.30M | $34.40M | $53.20M | $38.90M | $31.00M | $43.00M | $34.10M | $31.50M | $34.70M | $35.40M | $138.50M | $67.90M | $59.60M | $35.50M | - |
| TYVYT | - | - | - | - | - | - | - | - | - | $125.60M | - | - | - | - | - | - | - | - | - | - |
Eli Lilly and Company's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Oncology (58.87%), Immunology (27.13%), Neuroscience (12.66%), and Other Product (1.34%).
Eli Lilly and Company Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Other Foreign Countries | $2.95B | $2.85B | $2.70B | $2.42B | $3.28B |
| UNITED STATES | $21.79B | $18.19B | - | - | - |
| CHINA | $1.54B | $1.45B | $1.66B | $1.12B | - |
| Europe | $6.17B | $4.30B | $4.78B | $4.19B | $3.77B |
| JAPAN | $1.67B | $1.75B | $2.37B | $2.58B | $2.55B |
Eli Lilly and Company's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (63.86%), Europe (18.09%), Other Foreign Countries (8.63%), JAPAN (4.90%), and CHINA (4.51%).
Quarterly Revenue by Country
| Country | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $5.69B | $6.46B | $5.37B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| JAPAN | $363.90M | $439.00M | $390.80M | $455.60M | $387.20M | $395.00M | $487.70M | $454.40M | $410.20M | $534.80M | $595.00M | $665.40M | $571.80M | $664.00M | $660.10M | $666.70M | $592.30M | $709.20M | $641.50M | $653.20M |
| CHINA | $376.20M | $377.20M | $390.80M | $399.00M | $372.70M | $350.80M | $343.40M | $352.10M | $406.50M | $376.40M | $400.30M | $522.50M | $362.20M | $320.70M | $289.10M | $239.80M | $267.30M | - | - | - |
| Europe | $1.44B | $1.34B | $2.57B | $1.18B | $1.09B | $1.07B | $1.06B | $1.10B | $1.07B | $1.15B | $1.10B | $1.21B | $1.32B | $1.20B | $1.05B | $873.00M | $1.06B | $1.01B | $923.40M | $928.20M |
| Other Foreign Countries | $892.90M | $744.30M | $780.30M | $748.50M | $673.10M | $822.90M | $632.00M | $645.70M | $751.50M | $765.50M | $689.40M | $638.10M | $609.10M | $654.00M | $583.20M | $575.20M | $610.40M | $872.60M | $851.40M | $802.80M |
Eli Lilly and Company's latest quarterly revenue breakdown by geography, as of Mar 24: UNITED STATES (64.94%), Europe (16.43%), Other Foreign Countries (10.18%), CHINA (4.29%), and JAPAN (4.15%).
Eli Lilly and Company Peer Comparison by Revenue
LLY Revenue FAQ
What is Eli Lilly and Company’s yearly revenue?
Eli Lilly and Company's yearly revenue for 2023 was $34.12B, representing an increase of 19.56% compared to 2022. The company's yearly revenue for 2022 was $28.54B, representing an increase of 0.79% compared to 2021. LLY's yearly revenue for 2021 was $28.32B, representing an increase of 15.40% compared to 2020.
What is Eli Lilly and Company’s quarterly revenue?
Eli Lilly and Company's quarterly revenue for Q2 2024 was $11.3B, a 28.91% increase from the previous quarter (Q1 2024), and a 35.98% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $8.77B, a -6.26% decrease from the previous quarter (Q4 2023), and a 25.98% increase year-over-year (Q1 2023). LLY's quarterly revenue for Q4 2023 was $9.35B, a -1.53% decrease from the previous quarter (Q3 2023), and a 28.10% increase year-over-year (Q4 2022).
What is Eli Lilly and Company’s revenue growth rate?
Eli Lilly and Company's revenue growth rate for the last 3 years (2021-2023) was 20.50%, and for the last 5 years (2019-2023) was 52.89%.
What are Eli Lilly and Company’s revenue streams?
Eli Lilly and Company's revenue streams in c 23 are Collaboration and Other Revenue, and Product. Collaboration and Other Revenue generated $5.31B in revenue, accounting 15.56% of the company's total revenue, up 72.49% year-over-year. Product generated $28.81B in revenue, accounting 84.44% of the company's total revenue, up 13.16% year-over-year.
What is Eli Lilly and Company’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Eli Lilly and Company was Product. This segment made a revenue of $28.81B, representing 84.44% of the company's total revenue.